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Abstract
Background and Objective: The relative contribution of nitric oxide (NO) to the killing of Mycobacterium tuberculosis in
human tuberculosis (TB) is controversial, although this has been firmly established in rodents. Studies have demonstrated
that clinical strains of M. tuberculosis differ in susceptibility to NO, but how this correlates to drug susceptibility and clinical
outcome is not known.
Methods: In this study, 50 sputum smear- and culture-positive patients with pulmonary TB in Gondar, Ethiopia were
included. Clinical parameters were recorded and drug susceptibility profile and spoligotyping patterns were investigated.
NO susceptibility was studied by exposing the strains to the NO donor DETA/NO.
Results: Clinical isolates of M. tuberculosis showed a dose- and time-dependent response when exposed to NO. The most
frequent spoligotypes found were CAS1-Delhi and T3_ETH in a total of nine known spoligotypes and four orphan patterns.
There was a significant association between reduced susceptibility to NO (.10% survival after exposure to 1 mM DETA/NO)
and resistance against first-line anti-TB drugs, in particular isoniazid (INH). Patients infected with strains of M. tuberculosis
with reduced susceptibility to NO showed no difference in cure rate or other clinical parameters but a tendency towards
lower rate of weight gain after two months of treatment, independent of antibiotic resistance.
Conclusion:: There is a correlation between resistance to first-line anti-TB drugs and reduced NO susceptibility in clinical
strains of M. tuberculosis. Further studies including the mechanisms of reduced NO susceptibility are warranted and could
identify targets for new therapeutic interventions.
Citation: Idh J, Mekonnen M, Abate E, Wedajo W, Werngren J, et al. (2012) Resistance to First-Line Anti-TB Drugs Is Associated with Reduced Nitric Oxide
Susceptibility in Mycobacterium tuberculosis. PLoS ONE 7(6): e39891. doi:10.1371/journal.pone.0039891
Editor: T. Mark Doherty, Statens Serum Institute, Denmark
Received January 26, 2012; Accepted May 28, 2012; Published June 29, 2012
Copyright:  2012 Idh et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The study was supported by grants from the Swedish Research Council, Swedish International Development Agency (Sida) and the Swedish Heart-Lung
Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: jonna.idh@liu.se
Introduction
An important part of the host defence against Mycobacterium
tuberculosis is nitric oxide (NO) produced by activated macrophages
from L-arginine, molecular oxygen, and NADPH through the
activity of inducible NO synthase (iNOS) [1]. Several animal and
macrophage experiments have shown that NO and related
reactive nitrogen species (RNS) constitute a major host defence
mechanism against intracellular pathogens including, M. tubercu-
losis in both the acute and the latent phases of infection [2,3]. It has
also been shown that RNS are actively produced in human
tuberculosis (TB), although their relative importance is controver-
sial [4–9]. We have previously found that patients with TB have
lower levels of NO in exhaled air and lower levels of NO
metabolites in urine, compared to healthy controls [10], and that
nutritional supplements of L-arginine can mediate clinical
improvement in HIV-negative TB patients [11,12].
Bicyclic nitroimidazoles are drug candidates currently in
phase II trials for the treatment of tuberculosis [13,14]. They
are prodrugs, and one of the active metabolites generates RNS,
which has been suggested to mediate the major anaerobic effect
of the drug [15,16]. It has also been shown that NO can
contribute to the antimycobacterial action of the prodrug
isoniazid (INH) [17]. The exact mechanisms of INH action
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catalase-peroxidase (encoded by the katG gen), several INH-
derived intermediates and free radicals have been suggested to
be of importance [17,18].
Since previous studies have shown that susceptibility of
mycobacteria to RNS can be strain-dependent [19–24], we here
investigated the impact of relative NO susceptibility of M.
tuberculosis on the clinical course of TB and in relation to drug
resistance.
Materials and Methods
Patients
Patients presented here have previously been described in a
clinical trial on arginine-rich food supplementation (Clinical-
Trials.gov identifier: NCT00857402) were smear-positive pa-
tients with pulmonary TB, given Directly Observed Treatment
Short course (DOTS) at Gondar University Hospital, Ethiopia,
were consecutively asked to participate in the study. The
inclusion criteria were age 15 to 60 years, willingness to take
part in the study and no known chronic disease except TB and
HIV. Baseline data for age, sex, HIV serostatus, presence of
BCG scar, body mass index (BMI), body temperature, cough
and haemoptysis was registered. Chest X-ray findings were
graded as minimal, moderate or far advanced TB [25], and
after two months of treatment as normal, marked regression,
regression, stable disease or progression. Laboratory parameters,
erythrocyte sedimentation rate (ESR), baseline acid-fast bacilli
(AFB) smear grade, and NO metabolites in urine (as described
by Verdon et al [26]) were measured. In the first eleven
included subjects, exhaled NO was registered using an
chemiluminescence NO analyser (NIOX, Aerocrine AB, Swe-
den) as previously described [27].
Identification and Spoligotyping of M. tuberculosis
One sputum specimen from each patient was kept at 220uC (as
presented before) [28]. The sputum was decontaminated (modified
Petroff’s method) and processed according to standard protocols
[29] with subsequent inoculation on Lowenstein Jensen (LJ) slant
media. M. tuberculosis was identified by a PCR-based approach
built on genomic deletion analysis [30], and was carried out as
described [31]. Spoligotyping was performed using a standard
protocol [32] with the oligonucleotides DRa and DRb to amplify
the direct repeat (DR) regions.
Drug Susceptibility Testing
Drug susceptibility testing for streptomycin (SM, 2 mg/L),
isoniazid (INH, 1 mg/L), ethambutol (EMB, 5 mg/L) and
rifampin (RIF, 1 mg/L) was performed using the indirect
proportion method on LJ media, as recommended by WHO
[33,34]. When bacterial growth on the antibiotic-free media
reached 50–100 colonies, a growth more than 1% on antibiotic-
containing media was classified as resistant.
Susceptibility Testing for Nitric Oxide
M. tuberculosis from LJ medium was cultured in Middlebrook
7H9 broth supplemented with oleic acid-albumin-dextrose-cata-
lase (OADC) until log phase (determined by bacterial growth as
colony forming units (CFU) at different incubation periods, data
not shown). Following washing in sterile PBS/0.05% Tween 80, a
final concentration of 10
7 CFU/mL of bacteria were exposed in
duplicates to 1 mM diethylenetriamine/nitric oxide adduct
(DETA/NO, Sigma-Aldrich) and PBS (control) separately in
Middlebrook 7H9 medium without OADC for 24 hours at 37uC.
M. tuberculosis H37Rv (H37Rv) and M. bovis BCG (BCG) were used
as reference strains in dose-response studies. The antimicrobial
effect of DETA/NO was determined by viable count (CFUs) in
tenfold dilutions on Middlebrook 7H10 plates supplemented with
glycerol and 10% OADC.
Ethical Considerations
This study was conducted according to the principles
expressed in the Declaration of Helsinki and the study was
approved by the ethics committees at the Research and
Publication Office at Gondar College of Medicine and Health
Sciences, Ethiopian Science and Technology Commission, and
Karolinska Hospital, Sweden. All study subjects were included
only after obtaining written informed consent. For children
below 18 years informed and written consent was obtained from
parents or guardians.
Statistical Analyses
Data are presented as median and rang or first and third
quartiles (Q1–Q3) if not stated otherwise. Numerical data were
analysed with Mann-Whitney U-test, discrete data with Pearson’s
Chi-square test and Fisher’s exact test, and p-values of less than
0.05 were considered as statistically significant. Multiple logistic
regression analysis with a stepwise correction was applied on
variables with a p-value less than 0.1 in the univariate analysis.
Results
Baseline Characteristics
A total of 50 patients with confirmed culture- and smear-
positive pulmonary TB were included in the study. The median
age was 27 years (range 15–59), 50% (25/50) were female and
44% (22/50) were HIV-positive. Characteristics are presented in
detail in table 1.
Dose- and Time-dependent Response to NO
In order to determine doses and time points for the NO
exposure, initial experiments with three randomly selected clinical
isolates, one resistant to INH (coded RNI 027) and two fully
susceptible to first-line anti-TB drugs (RNI 065 and RNI 066),
were performed in duplicates. There was a dose- and time-
dependent killing when exposed to DETA/NO (0.1–10 mM)
(figure 1). After a 4-hour exposure to the selected dose of 1 mM
DETA/NO, the mean survival rate of the strains for the clinical
isolates was 68% (RNI 027), 62% (RNI 065), and 71% (RNI 066).
In H37Rv and BCG, the survival rate was 45% and 57%
respectively. The response was time-dependent and 24 hours post-
exposure, the survival decreased to 23% (RNI 027), 13% (RNI
065) and 12% (RNI 066) for the clinical isolates and to 9% and
17% for H37Rv and BCG, respectively (figure 1b).
Association between Reduced Susceptibility to NO and
Resistance to First-line anti-TB Drugs
Drug susceptibility testing showed an overall resistance rate to
first-line anti-TB drugs of 18% (9/50). The most frequent
resistance was found against INH (10%, 5/50) followed by SM
(6%, 3/50) and RIF (2%, 1/50). No strains resistant to EMB and
no multidrug-resistant (MDR) TB strains were isolated in this
study. The ratio of resistant strains did not differ between HIV-
positive and HIV-negative individuals (14% (3/22) vs. 21% (6/28),
p=0.713).
The median survival in the 50 clinical isolates, 24 hours post
exposure to 1 mM DETA/NO, was 10% and showed a variation
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(p,0.001, figure 2). For further comparison of susceptibility to NO
with drug resistance and clinical outcome, reduced susceptibility to
DETA/NO was defined as .10% survival (1 log10) after exposure
to 1 mM DETA/NO for 24 hours compared to the control
exposed to PBS.
Strikingly, no INH resistance was detected among NO-
susceptible strains and the median survival of INH-resistant
isolates exposed to DETA/NO was 53% (Q1–Q3, 32–57%, n=5)
compared to 10% (Q1–Q3, 0–25%, n=45, p=0.006) in INH-
susceptible isolates.
Table 1. Characteristics for patients infected with strains of M. tuberculosis susceptible to NO or with reduced susceptibility to NO.
NO-susceptible Reduced NO susceptibility
N Median (Q1–Q3) N Median (Q1–Q3) p
Characteristics Age (years) 26 26.0 (20.8–37.0) 24 27.0 (23.2–37.0) NS
BMI (kg/m
2) 26 16.8 (15.6–18.0) 24 15.8 (14.7–17.4) NS
Body temperature (uC) 25 37.6 (36.5–38.9) 24 37.8 (37.1–38.7) NS
ESR week 0 (mm/h) 26 72.5 (50.0–85.5) 24 78.0 (67.5–88.5) NS
ESR week 8 (mm/h) 25 44.0 (12.0–78.0) 24 41.0 (27.5–62.0) NS
N% ( n)N % ( n) p
Females 26 46.2 (12) 24 54.2 (13) NS
HIV 26 38.5 (10) 24 50.0 (12) NS
BCG 26 11.5 (3) 24 12.5 (3) NS
Cough week 0 26 100.0 (26) 24 100.0 (24) NS
Cough week 8 25 64.0 (16) 24 29.2 (7) ,0.05
Haemoptysis week 0 26 23.1 (6) 24 20.8 (5) NS
Haemoptysis week 8 25 8.0 (2) 24 4.2 (1) NS
Weight gain from week 0 to 8 25 100.0 (25) 24 83.3 (20) 0.05
Sputum conversion week 8 26 84.6 (22) 24 83.3 (20) NS
Chest X-ray week 0 Normal 19 0.0 (0) 16 0.0 (0) NS
Minimal 19 26.3 (14) 16 25.0 (4) NS
Moderately advanced 19 52.6 (10) 16 50.0 (8) NS
Far advanced 19 21.1 (4) 16 25.0 (4) NS
Chest X-ray week 8 Normal 16 0.0 (0) 15 6.7 (1) NS
Marked regression 16 6.3 (1) 15 13.3 (2) NS
Regression 16 62.5 (10) 15 66.7 (10) NS
No change 16 25.0 (4) 15 13.3 (2) NS
Progress 16 6.3 (1) 15 0.0 (0) NS
Outcome Cured 26 76.9 (20) 24 70.8 (17) NS
Died 26 3.8 (1) 24 0.0 (0) NS
Treatment failure 26 11.5 (3) 24 8.3 (2) NS
Defaulter 26 3.8 (1) 24 12.5 (3) NS
Transferred out 26 3.8 (1) 24 4.2 (1) NS
Antibiotic resistance Fully susceptible 26 96.2 (25) 22 66.7 (16) ,0.05
INH resistance 26 0.0 (0) 24 20.8 (5) ,0.05
SM resistance 26 3.8 (1) 24 8.3 (2) NS
EMB resistance 26 0.0 (0) 24 0.0 (0) NS
RIF resistance 26 0.0 (0) 24 4.2 (1) NS
N Median (Q1–Q3) N Median (Q1–Q3) p
NO production Urinary NO week 0 (mM) 26 1111 (792–1615) 24 1264 (931–1810) NS
Urinary NO week 8 (mM) 25 1067 (961–1976) 24 1436 (881–2276) NS
Exhaled NO week 0 (ppb) 11 15.8 (14.2–20.2) 8 12.4 (8.1–15.2) NS
Exhaled NO week 8 (ppb) 11 15.7 (11.3–19.5) 8 15.0 (11.1–24.1) NS
Q1–Q3 (quartile 1 to quartile 3); NO (nitric oxide); BMI (body mass index); ESR (sedimentation rate); INH (isoniazid); SM (streptomycin); EMB (ethambutol); RIF (rifampin).
NO-susceptible and reduced NO-susceptible strains defined as #10% and .10% survival respectively after exposure to 1 mM DETA/NO. All patients were smear positive
at week 0. Continuous data were tested with Mann-Whitney U-test and discrete data with Fisher’s exact test or Pearson’s Chi-square test.
doi:10.1371/journal.pone.0039891.t001
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tuberculosis
Infection with strains of M. tuberculosis with reduced susceptibility
to NO did not correlate to the final clinical outcome according to
WHO (cured, died, treatment failure, defaulter or transferred out;
table 1),butthere was a tendency to a lower rateof weight gain after
8 weeks of treatment (83% (20/24) vs. 100% (25/25), p=0.05).
Three out of the four study subjects who did not increase in weight
during the 8 first weeks of treatment were HIV-positive, but there
was no statistical difference in weight gain overall between HIV-
positive and HIV-negative TB patients (86% (18/21) vs. 96% (27/
28), p=0.301). Nor did patients infected with drug-resistant strains
differ in their rate of weight gain compared to patients with drug-
susceptible strains (8/9, 89% vs. 37/40, 93%, p=0.569).
Multiple Logistic Regression Analysis
The multiple logistic regression analysis showed that reduced
NO susceptibility was associated to drug resistance also when age,
sex, HIV status and supplementation of arginine-rich food were
included in in the analysis (OR 19.00; 95% CI (1.67–215.52),
p=0.019, n=50, table 2).
Spoligotype Patterns
Of the 50 clinical strains 47 (94%) were successfully typed by
conventional spoligotyping technique [32]. The isolates were
identified as five orphan spoligotypes and nine spoligotypes present
in the M. tuberculosis molecular markers database (SITVIT) and
compared to the fourth international spoligotyping database
(SpolDB4) for classification [35–37]. The most common spoligo-
types were CAS1-Delhi (28%, 13/47) and T3_ETH (23%, 11/47).
Although the spoligotype-based clusters differed in susceptibility to
NO, our sample size was not sufficient to investigate any significant
differences between the clusters (figure 2).
Discussion
ThemainfindingofthisstudyisthatreducedsusceptibilitytoNO
in clinical strains of M. tuberculosis was associated with resistance to
first-line drugs against TB. As previously reported, certain strains of
M. tuberculosis can to some extent resist RNS generated in vitro as
acidified nitrite (M. intracellulare 31F093T, KUMS 9007 [19], M.
tuberculosisCDC1551,CB3.3[23],M.bovis,M.tuberculosis79499[21],
aCstrainclusterdefinedbyIS6110-basedstrain-typing[20],andthe
genotypesG1,G2,S2,U[24]).Sincetheacidhasabactericidaleffect
in itself and actually potentiates the effect of NO [38], it has been
acknowledgedthatthenewgenerationNOdonors(DETA/NO)can
bettermimicaprolongedreleasewithlowlevelsofNOsimilartothe
productioninvivo[39].Indose-responseexperimentsforthreeclinical
strains,wefoundthattherewasadose-dependentkillingbyonelog10
at 1 mM DETA/NO and by 2 log10 for 10 mM DETA/NO. The
level of inhibition by NO at 24 hours was between 0.5 to 2 log10 for
1 mM DETA/NO, which could be compared to the early effect of
bactericidal drugs such as INH [40]. To discriminate difference in
susceptibility to NO between clinical strains, we used a cut-off for
reducedNOsusceptibilityat10%survivalafter24hourscomparedto
control,whichissimilartothewildtypedistributionusedfordefining
criticalconcentrationsforM.tuberculosis[33].LowerdosesofDETA/
NOhavebeenusedtoinduceexpressionoflatency-associatedgenes
such as dosR [41,42]. The effect of NO is likely to be increased if
investigatedatlatertimepointsasforanti-TBdrugs,sincekillingofM.
tuberculosis takes more time relative to other bacteria with higher
replicationratessuchasE.coli.Theanalysiswasblindedtoantibiotic
resistancedata,andahighlevelofantibioticresistancewasobserved
in the isolates with reduced NO susceptibility. Strikingly, no INH
resistance was detected among NO-susceptible strains but on the
other hand reduced NO susceptibility was not exclusively found
amongINH-resistantstrains.INHisaprodrugthatneedsactivation
by the katG-encoded mycobacterial catalase-peroxidase, where
severalINH-derivedintermediatesincludingfreeradicalshavebeen
suggested to contribute to the overall antimycobacterial action of
INH [17,18]. We did not verify the genetic location of the INH
resistance, although the katG-mutation is the predominant cause of
INH resistance in strains of M. tuberculosis from Ethiopia [43]. It has
previouslybeenshownthatthelossofkatGcouldrenderthebacteria
susceptible to reactive oxygen species (ROS) and RNS, and a
compensatoryup-regulationofthealkylhydroperoxidase(ahpC)gene
could be the explanation for the increased resistance to NO as a
compensatory survival strategy of INH-resistant bacteria [44–46].
Other candidates for antioxidant systems up-regulated by M.
tuberculosis during oxidative stress are thioredoxin-dependent perox-
idases (TPx), resulting in tolerance to peroxides produced by the
immunesystem[42].Mostlikely,itisacombinationoftheexpression
of genes upon exposure to reactive species, the resistance of the M.
tuberculosis cell wall itself, and up-regulation of genes to repair
damaged proteins and DNA, that result in reduced susceptibility
against ROS and RNS in M. tuberculosis [42]. The most frequent
Figure 1. Dose- and time-dependent killing of M. tuberculosis
exposed to NO. Survival of three clinical strains, H37Rv and BCG after
exposure to 1 mM of the NO donor DETA/NO for 4 and 24 hours (A).
Survival of the three clinical strains exposed to different doses of DETA/
NO for 24 hours (B). Survival was determined through viable count
(colony forming units, CFU) and each point represents a mean value of
duplicates.
doi:10.1371/journal.pone.0039891.g001
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identification of genetic relationship among the isolates is likely to
better have identified differences among the strains in respect to
susceptibility to NO.
Although the small sample size is a limitation, no correlation was
found between susceptibility of M. tuberculosis to NO and treatment
outcome,buttherewasatendencytowardslowerrateofweightgain
after8weeksoftreatment,insubjectsinfectedwithM.tuberculosiswith
reduced susceptibility to NO. To draw a more definitive conclusion
on whether this result was confounded by the presence of
antimycobacterial drug resistance, a larger sample sizeis needed.
In a situation of increasing MDR and extensively drug-resistant
(XDR) TB, new drug targets are needed [47]. NO is produced in
activated macrophages during TB [1,8,9] and based on the
correlation between reduced susceptibility to NO and resistance to
first-lineanti-TBdrugs,therelativeimportanceofoxidativedefence
mechanisms inM. tuberculosis needs to be further investigated.
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